Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s stock price was down 6.2% on Tuesday . The company traded as low as $5.09 and last traded at $5.15. Approximately 902,594 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 1,757,911 shares. The stock had previously closed at $5.49.
Analysts Set New Price Targets
Several research firms have recently issued reports on XERS. Piper Sandler restated a "neutral" rating and set a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners raised their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Finally, Jefferies Financial Group restated a "buy" rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $6.10.
Check Out Our Latest Report on Xeris Biopharma
Xeris Biopharma Stock Performance
The stock has a fifty day simple moving average of $4.30 and a two-hundred day simple moving average of $3.59. The stock has a market cap of $678.88 million, a PE ratio of -9.80 and a beta of 1.37.
Insider Activity
In related news, insider Beth Hecht sold 40,000 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. The trade was a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.56% of the company's stock.
Institutional Investors Weigh In On Xeris Biopharma
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Xeris Biopharma by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock valued at $26,778,000 after buying an additional 133,738 shares during the last quarter. Geode Capital Management LLC boosted its stake in Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock valued at $11,364,000 after acquiring an additional 17,956 shares during the last quarter. AIGH Capital Management LLC boosted its stake in Xeris Biopharma by 17.8% during the 4th quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company's stock valued at $8,729,000 after acquiring an additional 389,192 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock worth $7,115,000 after acquiring an additional 500,120 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after purchasing an additional 502,853 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Read More
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
